EGFR and lung cancer: Some studies have shown that lung cancer patients with EGFR mutation who are treated with targeted TKIs, such as erlotinib, afatinib, or gefitinib, show longer progression-free survival and higher objective radiographic response rates than patients treated with standard first-line chemotherapy [4, 5].